General Information of Drug Transporter (DT)
DT ID	DTD0246 Transporter Info
Gene Name	SLC28A3
Protein Name	Concentrative Na(+)-nucleoside cotransporter 3
Gene ID	64078
UniProt ID	Q9HAS3
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs4877847
Site of GPD	chr9:84331502 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	C=0.4860/2434 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele C)		[ 1]
Doxorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele C)		[ 1]
Anthracyclines And Related Substances	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.		[ 2]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.		[ 1]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.		[ 1]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele C.		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele C.		[ 1]
Anthracyclines	N.A.	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.		[ 2]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC, or increased likelihood as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines.		[ 2]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the toxicity to anthracyclines.		[ 2]
Genetic Polymorphism	rs7853758
Site of GPD	chr9:84286011 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.2027/1015 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         17 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 1]
Doxorubicin	Drug Info	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 1]
Anthracyclines And Related Substances	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Neuroblastoma, Osteosarcoma or Lymphoma as compared to allele G.		[ 5]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 1]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 1]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is not associated with likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.		[ 6]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is not associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele G.		[ 7]
Paclitaxel	N.A.	Cardiotoxicity	Allele A is not associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele G.		[ 7]
Trastuzumab	N.A.	Cardiotoxicity	Allele A is not associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele G.		[ 7]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is not associated with increased likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.		[ 8]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Neuroblastoma, Osteosarcoma or Lymphoma as compared to allele G.		[ 5]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Neuroblastoma, Osteosarcoma or Lymphoma as compared to allele G.		[ 5]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 2]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 2]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Genotype AA is associated with increased likelihood of Cardiotoxicity when exposed to anthracyclines and related substances in children with Acute lymphoblastic leukemia as compared to genotypes AG + GG.		[ 7]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 AA genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AG or GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Daunorubicin	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 AA genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AG or GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Doxorubicin	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 AA genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AG or GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Gemcitabine	N.A.	Neutropenia	Genotype GG is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.		[ 9]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 GG genotype and Neoplasms may have increased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AA or AG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Daunorubicin	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 GG genotype and Neoplasms may have increased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AA or AG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Doxorubicin	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 GG genotype and Neoplasms may have increased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the AA or AG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Cyclophosphamide	N.A.	Cardiotoxicity	Genotypes AA + AG is not associated with decreased likelihood of cardiotoxicity when treated with cyclophosphamide, doxorubicin, prednisolone and vincristine in people with Lymphoma, B-Cell as compared to genotype GG.		[ 10]
Doxorubicin	N.A.	Cardiotoxicity	Genotypes AA + AG is not associated with decreased likelihood of cardiotoxicity when treated with cyclophosphamide, doxorubicin, prednisolone and vincristine in people with Lymphoma, B-Cell as compared to genotype GG.		[ 10]
Prednisolone	N.A.	Cardiotoxicity	Genotypes AA + AG is not associated with decreased likelihood of cardiotoxicity when treated with cyclophosphamide, doxorubicin, prednisolone and vincristine in people with Lymphoma, B-Cell as compared to genotype GG.		[ 10]
Vincristine	N.A.	Cardiotoxicity	Genotypes AA + AG is not associated with decreased likelihood of cardiotoxicity when treated with cyclophosphamide, doxorubicin, prednisolone and vincristine in people with Lymphoma, B-Cell as compared to genotype GG.		[ 10]
Daunorubicin	N.A.	Left Ventricular Dysfunction	Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.		[ 8]
Doxorubicin	N.A.	Left Ventricular Dysfunction	Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.		[ 8]
Epirubicin	N.A.	Left Ventricular Dysfunction	Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.		[ 8]
Doxorubicin	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with decreased likelihood of cardiotoxicity when treated with doxorubicin in children with Neoplasms, Wilms Tumor, Sarcoma, Ewing's, Hodgkin Disease, Lymphoma, Non-Hodgkin, Osteosarcoma or Neuroblastoma as compared to genotype GG.		[ 12]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.		[ 8]
Daunorubicin	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.		[ 8]
Doxorubicin	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.		[ 8]
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with decreased likelihood of cardiotoxicity when treated with doxorubicin in children with Neoplasms, Wilms Tumor, Sarcoma, Ewing's, Hodgkin Disease, Lymphoma, Non-Hodgkin, Osteosarcoma or Neuroblastoma as compared to genotype GG.		[ 12]
Daunorubicin	N.A.	Cardiotoxicity	Genotypes AA + AG is associated with decreased likelihood of cardiotoxicity when treated with doxorubicin in children with Neoplasms, Wilms Tumor, Sarcoma, Ewing's, Hodgkin Disease, Lymphoma, Non-Hodgkin, Osteosarcoma or Neuroblastoma as compared to genotype GG.		[ 12]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Anthracyclines And Related Substances	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 AG genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Daunorubicin	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 AG genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Doxorubicin	N.A.	Cardiotoxicity	Pediatric patients with the rs7853758 AG genotype and Neoplasms may have decreased likelihood of cardiotoxicity when treated with anthracyclines as compared to pediatric patients with the GG genotype. Other genetic and clinical factors may also influence development of cardiotoxicity.		[ 8]
Genetic Polymorphism	rs885004
Site of GPD	chr9:84294635 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.1320/661 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 1]
Doxorubicin	Drug Info	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 1]
Anthracyclines And Related Substances	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 2]
Daunorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 1]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 1]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.		[ 2]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.		[ 1]
Anthracyclines	N.A.	Neoplasm	Correlated with the decreased likelihood of cardiotoxicity in patients (compare with allele C)		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.		[ 2]
Genetic Polymorphism	rs10868138
Site of GPD	chr9:84302386 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.8850/1751 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Valganciclovir	N.A.	Neutropenia	Genotypes CC + CT is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype TT.		[ 12]
Mercaptopurine	N.A.	Leukopenia	Genotypes CC + CT is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 13]
Methotrexate	N.A.	Leukopenia	Genotypes CC + CT is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 13]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Neurotoxicity Syndromes	Genotype TT is not associated with increased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.		[ 14]
Genetic Polymorphism	rs4877831
Site of GPD	chr9:84284969 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G
Minor Allele Frequency	C=0.5300/1048 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Neutropenia	Genotype GG is not associated with metabolism of gemcitabine as compared to genotypes CC + CG.		[ 15]
Genetic Polymorphism	rs11140490
Site of GPD	chr9:84278398 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.7900/1563 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Doxorubicin	N.A.	Neutropenia	Genotype AA is associated with increased sensitivity to doxorubicin in Peripheral blood mononuclear cells from pediatric patients reprogramed to hiPSCs (cardiomyocytes) as compared to genotype AG.		[ 16]
Genetic Polymorphism	rs7867504
Site of GPD	chr9:84305321 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.4280/847 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Gemcitabine	N.A.	Neutropenia	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.		[ 9]
Gemcitabine Triphosphate	N.A.	Left Ventricular Dysfunction	Genotype CC is associated with increased formation of gemcitabine triphosphate.		[ 15]
Gemcitabine	N.A.	Neoplasms	Genotype CC is associated with increased formation of gemcitabine triphosphate.		[ 15]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Gemcitabine	N.A.	Neurotoxicity Syndromes	Genotypes CC + CT is not associated with increased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to genotype TT.		[ 17]
Paclitaxel	N.A.	Neurotoxicity Syndromes	Genotypes CC + CT is not associated with increased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to genotype TT.		[ 17]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Neoplasms	Patients with the CT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.		[ 15]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Neoplasms	Patients with the TT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.		[ 15]
Genetic Polymorphism	rs17343066
Site of GPD	chr9:84331158 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.6560/1298 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Antineoplastic Agents	N.A.	Neurotoxicity Syndromes	Genotype AA is associated with decreased likelihood of Neurotoxicity Syndromes when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 18]
Ara-ctp	N.A.	Cardiotoxicity	Genotype AA is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 19]
Genetic Polymorphism	rs7035753
Site of GPD	chr9:84340767 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.5810/1149 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Cardiotoxicity	Allele T is associated with 6-mercaptopurine and methyl-mercaptopurine nucleotide levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 20]
Genetic Polymorphism	rs17087144
Site of GPD	chr9:84349803 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.7610/1506 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Cardiotoxicity	Allele A is associated with 6-mercaptopurine and methyl-mercaptopurine nucleotide levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 20]
Genetic Polymorphism	rs7043257
Site of GPD	chr9:84338759 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.2200/435 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Cardiotoxicity	Allele C is associated with 6-mercaptopurine and methyl-mercaptopurine nucleotide levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 20]
Genetic Polymorphism	rs17428030
Site of GPD	chr9:84338706 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.9630/1905 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Mercaptopurine	N.A.	Cardiotoxicity	Allele G is associated with TPMT activity when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 20]
Thioguanine	N.A.	Cardiotoxicity	Allele G is associated with TPMT activity when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 20]
Genetic Polymorphism	rs4588940
Site of GPD	chr9:84326705 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.6410/1268 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Cardiotoxicity	Allele G is associated with 6-mercaptopurine and methyl-mercaptopurine nucleotide levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 20]
Genetic Polymorphism	rs4305983
Site of GPD	chr9:84329536 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.1930/381 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mercaptopurine	N.A.	Cardiotoxicity	Allele A is associated with 6-mercaptopurine and methyl-mercaptopurine nucleotide levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 20]
References
1	Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81.
2	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8.
3	Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity. Ther Drug Monit. 2023 Jun 01;45(3):337-344.
4	Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016 Feb;17(3):231-40.
5	Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017 Oct;27(10):378-385.
6	Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients. Br J Clin Pharmacol. 2024 Aug;90(8):1782-1789.
7	Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer. 2018 Jul 03;18(1):704.
8	Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients. Pharmacogenomics. 2022 Apr;23(5):291-301.
9	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15;116(22):5325-35.
10	Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics. 2015;16(4):361-72.
11	The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors. J Pediatr Hematol Oncol. 2024 Jan 01;46(1):e65-e70.
12	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
13	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015;16(10):1119-34.
14	Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer. 2009 Jan;63(1):121-7.
15	SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer. 2014 Jan 21;110(2):304-12.
16	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. Circulation. 2022 Jan 25;145(4):279-294.
17	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer. 2014 Mar;50(4):698-705.
18	Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study. JCO Precis Oncol. 2023 Mar;7:e2200580.
19	Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018 Sep 01;19(14):1101-1110.
20	Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes. Pharmacogenomics. 2014 Mar;15(4):433-47.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.